ID   RASH_HUMAN              Reviewed;         189 AA.
AC   P01112; B5BUA0; Q14080; Q6FHV9; Q9BR65; Q9UCE2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   22-JUL-2015, entry version 202.
DE   RecName: Full=GTPase HRas;
DE   AltName: Full=H-Ras-1;
DE   AltName: Full=Ha-Ras;
DE   AltName: Full=Transforming protein p21;
DE   AltName: Full=c-H-ras;
DE   AltName: Full=p21ras;
DE   Contains:
DE     RecName: Full=GTPase HRas, N-terminally processed;
DE   Flags: Precursor;
GN   Name=HRAS; Synonyms=HRAS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6298635; DOI=10.1038/302033a0;
RA   Capon D.J., Chen E.Y., Levinson A.D., Seeburg P.H., Goeddel D.V.;
RT   "Complete nucleotide sequences of the T24 human bladder carcinoma
RT   oncogene and its normal homologue.";
RL   Nature 302:33-37(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6844927; DOI=10.1126/science.6844927;
RA   Reddy E.P.;
RT   "Nucleotide sequence analysis of the T24 human bladder carcinoma
RT   oncogene.";
RL   Science 220:1061-1063(1983).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6087347; DOI=10.1073/pnas.81.15.4771;
RA   Sekiya T., Fushimi M., Hori H., Hirohashi S., Nishimura S.,
RA   Sugimura T.;
RT   "Molecular cloning and the total nucleotide sequence of the human c-
RT   Ha-ras-1 gene activated in a melanoma from a Japanese patient.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:4771-4775(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, INTERACTION WITH
RP   GNB2L1, SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF SER-17.
RX   PubMed=14500341;
RA   Guil S., de La Iglesia N., Fernandez-Larrea J., Cifuentes D.,
RA   Ferrer J.C., Guinovart J.J., Bach-Elias M.;
RT   "Alternative splicing of the human proto-oncogene c-H-ras renders a
RT   new Ras family protein that trafficks to cytoplasm and nucleus.";
RL   Cancer Res. 63:5178-5187(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction
RT   sequenced by the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (SEP-2006) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung carcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PROTEIN SEQUENCE OF 1-41; 43-117; 129-161 AND 170-185, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Calvo F., Kolch W.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37.
RX   PubMed=6290897; DOI=10.1038/300143a0;
RA   Tabin C.J., Bradley S.M., Bargmann C.I., Weinberg R.A.,
RA   Papageorge A.G., Scolnick E.M., Dhar R., Lowy D.R., Chang E.H.;
RT   "Mechanism of activation of a human oncogene.";
RL   Nature 300:143-149(1982).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-16.
RX   PubMed=3670300;
RA   Honkawa H., Masahashi W., Hashimoto S., Hashimoto-Gotoh T.;
RT   "Identification of the principal promoter sequence of the c-H-ras
RT   transforming oncogene: deletion analysis of the 5'-flanking region by
RT   focus formation assay.";
RL   Mol. Cell. Biol. 7:2933-2940(1987).
RN   [15]
RP   PROTEIN SEQUENCE OF 108-117 AND 132-153.
RX   PubMed=8393791; DOI=10.1111/j.1432-1033.1993.tb18056.x;
RA   Loew A., Sprinzl M., Faulhammer H.G.;
RT   "Affinity labeling of c-H-ras p21 consensus elements with periodate-
RT   oxidized GDP and GTP.";
RL   Eur. J. Biochem. 215:473-479(1993).
RN   [16]
RP   MUTAGENESIS OF ALA-83; ASP-119 AND THR-144.
RX   PubMed=3088563; DOI=10.1073/pnas.83.13.4607;
RA   Feig L.A., Pan B.-T., Roberts T.M., Cooper G.M.;
RT   "Isolation of ras GTP-binding mutants using an in situ colony-binding
RT   assay.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:4607-4611(1986).
RN   [17]
RP   MUTAGENESIS OF 164-ARG-GLN-165.
RX   PubMed=3011420;
RA   Lacal J.C., Anderson P.S., Aaronson S.A.;
RT   "Deletion mutants of Harvey ras p21 protein reveal the absolute
RT   requirement of at least two distant regions for GTP-binding and
RT   transforming activities.";
RL   EMBO J. 5:679-687(1986).
RN   [18]
RP   PALMITOYLATION AT CYS-181 AND CYS-184.
RX   PubMed=2661017; DOI=10.1016/0092-8674(89)90054-8;
RA   Hancock J.F., Magee A.I., Childs J.E., Marshall C.J.;
RT   "All ras proteins are polyisoprenylated but only some are
RT   palmitoylated.";
RL   Cell 57:1167-1177(1989).
RN   [19]
RP   PALMITOYLATION AT CYS-181 AND CYS-184, ISOPRENYLATION AT CYS-186,
RP   METHYLATION AT CYS-186, AND MUTAGENESIS OF CYS-181 AND CYS-184.
RX   PubMed=8626715; DOI=10.1074/jbc.271.19.11541;
RA   Dudler T., Gelb M.H.;
RT   "Palmitoylation of Ha-Ras facilitates membrane binding, activation of
RT   downstream effectors, and meiotic maturation in Xenopus oocytes.";
RL   J. Biol. Chem. 271:11541-11547(1996).
RN   [20]
RP   S-NITROSYLATION AT CYS-118, FUNCTION, MASS SPECTROMETRY, AND
RP   MUTAGENESIS OF CYS-118.
RX   PubMed=9020151; DOI=10.1074/jbc.272.7.4323;
RA   Lander H.M., Hajjar D.P., Hempstead B.L., Mirza U.A., Chait B.T.,
RA   Campbell S., Quilliam L.A.;
RT   "A molecular redox switch on p21(ras). Structural basis for the nitric
RT   oxide-p21(ras) interaction.";
RL   J. Biol. Chem. 272:4323-4326(1997).
RN   [21]
RP   INTERACTION WITH IKZF3.
RX   PubMed=10369681; DOI=10.1093/emboj/18.12.3419;
RA   Romero F., Martinez-A C., Camonis J., Rebollo A.;
RT   "Aiolos transcription factor controls cell death in T cells by
RT   regulating Bcl-2 expression and its cellular localization.";
RL   EMBO J. 18:3419-3430(1999).
RN   [22]
RP   INTERACTION WITH RAPGEF2.
RX   PubMed=10608844; DOI=10.1074/jbc.274.53.37815;
RA   Liao Y., Kariya K., Hu C.-D., Shibatohge M., Goshima M., Okada T.,
RA   Watari Y., Gao X., Jin T.-G., Yamawaki-Kataoka Y., Kataoka T.;
RT   "RA-GEF, a novel Rap1A guanine nucleotide exchange factor containing a
RT   Ras/Rap1A-associating domain, is conserved between nematode and
RT   humans.";
RL   J. Biol. Chem. 274:37815-37820(1999).
RN   [23]
RP   INTERACTION WITH PLCE1, CHARACTERIZATION OF VARIANT VAL-12, AND
RP   MUTAGENESIS OF SER-17; ASN-26; VAL-29; TYR-32; PRO-34; THR-35; GLU-37;
RP   ASP-38 AND SER-39.
RX   PubMed=11022048; DOI=10.1074/jbc.M008324200;
RA   Song C., Hu C.-D., Masago M., Kariya K., Yamawaki-Kataoka Y.,
RA   Shibatohge M., Wu D., Satoh T., Kataoka T.;
RT   "Regulation of a novel human phospholipase C, PLCepsilon, through
RT   membrane targeting by Ras.";
RL   J. Biol. Chem. 276:2752-2757(2001).
RN   [24]
RP   INTERACTION WITH RAPGEF2.
RX   PubMed=11598133; DOI=10.1074/jbc.M108373200;
RA   Pham N., Rotin D.;
RT   "Nedd4 regulates ubiquitination and stability of the guanine-
RT   nucleotide exchange factor CNrasGEF.";
RL   J. Biol. Chem. 276:46995-47003(2001).
RN   [25]
RP   IDENTIFICATION IN A COMPLEX WITH RASGRP1 AND DGKZ.
RX   PubMed=11257115; DOI=10.1083/jcb.152.6.1135;
RA   Topham M.K., Prescott S.M.;
RT   "Diacylglycerol kinase zeta regulates Ras activation by a novel
RT   mechanism.";
RL   J. Cell Biol. 152:1135-1143(2001).
RN   [26]
RP   INTERACTION WITH PDE6D.
RX   PubMed=11980706; DOI=10.1093/emboj/21.9.2095;
RA   Hanzal-Bayer M., Renault L., Roversi P., Wittinghofer A., Hillig R.C.;
RT   "The complex of Arl2-GTP and PDE delta: from structure to function.";
RL   EMBO J. 21:2095-2106(2002).
RN   [27]
RP   LIPIDATION AT CYS-184, AND MUTAGENESIS OF CYS-184.
RX   PubMed=12684535; DOI=10.1073/pnas.0735842100;
RA   Oliva J.L., Perez-Sala D., Castrillo A., Martinez N., Canada F.J.,
RA   Bosca L., Rojas J.M.;
RT   "The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and
RT   activates H-Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4772-4777(2003).
RN   [28]
RP   CHARACTERIZATION OF CSTLO VARIANT VAL-12.
RX   PubMed=15546861; DOI=10.1074/jbc.M410775200;
RA   Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.;
RT   "Dephosphorylation of tau by protein phosphatase 5: impairment in
RT   Alzheimer's disease.";
RL   J. Biol. Chem. 280:1790-1796(2005).
RN   [29]
RP   PALMITOYLATION AT CYS-181 AND CYS-184.
RX   PubMed=16000296; DOI=10.1074/jbc.M504113200;
RA   Swarthout J.T., Lobo S., Farh L., Croke M.R., Greentree W.K.,
RA   Deschenes R.J., Linder M.E.;
RT   "DHHC9 and GCP16 constitute a human protein fatty acyltransferase with
RT   specificity for H- and N-Ras.";
RL   J. Biol. Chem. 280:31141-31148(2005).
RN   [30]
RP   PALMITOYLATION AT CYS-181 AND CYS-184, MUTAGENESIS OF CYS-181 AND
RP   CYS-184, AND SUBCELLULAR LOCATION.
RX   PubMed=15705808; DOI=10.1126/science.1105654;
RA   Rocks O., Peyker A., Kahms M., Verveer P.J., Koerner C.,
RA   Lumbierres M., Kuhlmann J., Waldmann H., Wittinghofer A.,
RA   Bastiaens P.I.H.;
RT   "An acylation cycle regulates localization and activity of
RT   palmitoylated Ras isoforms.";
RL   Science 307:1746-1752(2005).
RN   [31]
RP   INTERACTION WITH TBC1D10C.
RX   PubMed=17230191; DOI=10.1038/nature05476;
RA   Pan F., Sun L., Kardian D.B., Whartenby K.A., Pardoll D.M., Liu J.O.;
RT   "Feedback inhibition of calcineurin and Ras by a dual inhibitory
RT   protein Carabin.";
RL   Nature 445:433-436(2007).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=2448879; DOI=10.1126/science.2448879;
RA   de Vos A.M., Tong L., Milburn M.V., Matias P.M., Jancarik J.,
RA   Noguchi S., Nishimura S., Miura K., Ohtsuka E., Kim S.-H.;
RT   "Three-dimensional structure of an oncogene protein: catalytic domain
RT   of human c-H-ras p21.";
RL   Science 239:888-893(1988).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX   PubMed=2476675; DOI=10.1038/341209a0;
RA   Pai E.F., Kabsch W., Krengel U., Holmes K.C., John J.,
RA   Wittinghofer A.;
RT   "Structure of the guanine-nucleotide-binding domain of the Ha-ras
RT   oncogene product p21 in the triphosphate conformation.";
RL   Nature 341:209-214(1989).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS).
RX   PubMed=2196171;
RA   Pai E.F., Krengel U., Petsko G.A., Goody R.S., Kabsch W.,
RA   Wittinghofer A.;
RT   "Refined crystal structure of the triphosphate conformation of H-ras
RT   p21 at 1.35-A resolution: implications for the mechanism of GTP
RT   hydrolysis.";
RL   EMBO J. 9:2351-2359(1990).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=1899707; DOI=10.1016/0022-2836(91)90753-S;
RA   Tong L.A., de Vos A.M., Milburn M.V., Kim S.H.;
RT   "Crystal structures at 2.2-A resolution of the catalytic domains of
RT   normal ras protein and an oncogenic mutant complexed with GDP.";
RL   J. Mol. Biol. 217:503-516(1991).
RN   [36]
RP   STRUCTURE BY NMR OF 1-166.
RX   PubMed=8142349; DOI=10.1021/bi00178a008;
RA   Kraulis P.J., Domaille P.J., Campbell-Burk S.L., van Aken T.,
RA   Laue E.D.;
RT   "Solution structure and dynamics of ras p21.GDP determined by
RT   heteronuclear three- and four-dimensional NMR spectroscopy.";
RL   Biochemistry 33:3515-3531(1994).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-166 IN COMPLEX WITH RASGAP.
RX   PubMed=9219684; DOI=10.1126/science.277.5324.333;
RA   Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmuller L., Lautwein A.,
RA   Schmitz F., Wittinghofer A.;
RT   "The Ras-RasGAP complex: structural basis for GTPase activation and
RT   its loss in oncogenic Ras mutants.";
RL   Science 277:333-338(1997).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.26 ANGSTROMS).
RX   PubMed=10574788; DOI=10.1016/S0969-2126(00)80021-0;
RA   Scheidig A.J., Burmester C., Goody R.S.;
RT   "The pre-hydrolysis state of p21(ras) in complex with GTP: new
RT   insights into the role of water molecules in the GTP hydrolysis
RT   reaction of ras-like proteins.";
RL   Structure 7:1311-1324(1999).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP
RP   ANALOGS.
RX   PubMed=12213964; DOI=10.1073/pnas.192453199;
RA   Hall B.E., Bar-Sagi D., Nassar N.;
RT   "The structural basis for the transition from Ras-GTP to Ras-GDP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:12138-12142(2002).
RN   [40]
RP   STRUCTURE BY NMR OF 1-166, S-NITROSYLATION, FUNCTION, MUTAGENESIS OF
RP   CYS-118, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12740440; DOI=10.1073/pnas.1037299100;
RA   Williams J.G., Pappu K., Campbell S.L.;
RT   "Structural and biochemical studies of p21Ras S-nitrosylation and
RT   nitric oxide-mediated guanine nucleotide exchange.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:6376-6381(2003).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1-166 IN COMPLEXES WITH GTP
RP   ANALOG, CHARACTERIZATION OF VARIANTS LEU-61 AND LYS-61, AND
RP   MUTAGENESIS OF GLN-61.
RX   PubMed=18073111; DOI=10.1016/j.str.2007.10.011;
RA   Buhrman G., Wink G., Mattos C.;
RT   "Transformation efficiency of RasQ61 mutants linked to structural
RT   features of the switch regions in the presence of Raf.";
RL   Structure 15:1618-1629(2007).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-166 IN COMPLEX WITH RASSF5.
RX   PubMed=18596699; DOI=10.1038/emboj.2008.125;
RA   Stieglitz B., Bee C., Schwarz D., Yildiz O., Moshnikova A.,
RA   Khokhlatchev A., Herrmann C.;
RT   "Novel type of Ras effector interaction established between tumour
RT   suppressor NORE1A and Ras switch II.";
RL   EMBO J. 27:1995-2005(2008).
RN   [43]
RP   VARIANT SER-12.
RX   PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT   squamous-cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [44]
RP   VARIANT LYS-61, AND INVOLVEMENT IN SUSCEPTIBILITY TO HURTHLE CELL
RP   THYROID CARCINOMA.
RX   PubMed=12727991; DOI=10.1210/jc.2002-021907;
RA   Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K.,
RA   Dorn G.W. II, Tallini G., Kroll T.G., Nikiforov Y.E.;
RT   "RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid
RT   tumors: evidence for distinct molecular pathways in thyroid follicular
RT   carcinoma.";
RL   J. Clin. Endocrinol. Metab. 88:2318-2326(2003).
RN   [45]
RP   VARIANTS CSTLO ALA-12; SER-12; VAL-12 AND ASP-13.
RX   PubMed=16170316; DOI=10.1038/ng1641;
RA   Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y.,
RA   Filocamo M., Kato K., Suzuki Y., Kure S., Matsubara Y.;
RT   "Germline mutations in HRAS proto-oncogene cause Costello syndrome.";
RL   Nat. Genet. 37:1038-1040(2005).
RN   [46]
RP   VARIANTS CSTLO ALA-12; SER-12 AND CYS-13.
RX   PubMed=16329078; DOI=10.1002/ajmg.a.31047;
RA   Gripp K.W., Lin A.E., Stabley D.L., Nicholson L., Scott C.I. Jr.,
RA   Doyle D., Aoki Y., Matsubara Y., Zackai E.H., Lapunzina P.,
RA   Gonzalez-Meneses A., Holbrook J., Agresta C.A., Gonzalez I.L.,
RA   Sol-Church K.;
RT   "HRAS mutation analysis in Costello syndrome: genotype and phenotype
RT   correlation.";
RL   Am. J. Med. Genet. A 140:1-7(2006).
RN   [47]
RP   VARIANTS CSTLO SER-12; CYS-12; GLU-12; ALA-12 AND ARG-117.
RX   PubMed=16443854; DOI=10.1136/jmg.2005.040352;
RA   Kerr B., Delrue M.-A., Sigaudy S., Perveen R., Marche M., Burgelin I.,
RA   Stef M., Tang B., Eden O.B., O'Sullivan J., De Sandre-Giovannoli A.,
RA   Reardon W., Brewer C., Bennett C., Quarell O., M'Cann E., Donnai D.,
RA   Stewart F., Hennekam R., Cave H., Verloes A., Philip N., Lacombe D.,
RA   Levy N., Arveiler B., Black G.;
RT   "Genotype-phenotype correlation in Costello syndrome: HRAS mutation
RT   analysis in 43 cases.";
RL   J. Med. Genet. 43:401-405(2006).
RN   [48]
RP   VARIANTS CSTLO SER-12 AND THR-146.
RX   PubMed=17054105; DOI=10.1002/humu.20431;
RA   Zampino G., Pantaleoni F., Carta C., Cobellis G., Vasta I., Neri C.,
RA   Pogna E.A., De Feo E., Delogu A., Sarkozy A., Atzeri F., Selicorni A.,
RA   Rauen K.A., Cytrynbaum C.S., Weksberg R., Dallapiccola B.,
RA   Ballabio A., Gelb B.D., Neri G., Tartaglia M.;
RT   "Diversity, parental germline origin, and phenotypic spectrum of de
RT   novo HRAS missense changes in Costello syndrome.";
RL   Hum. Mutat. 28:265-272(2007).
RN   [49]
RP   VARIANTS CMEMS VAL-12; SER-12; LYS-22 AND LYS-63.
RX   PubMed=17412879; DOI=10.1136/jmg.2007.049270;
RA   van der Burgt I., Kupsky W., Stassou S., Nadroo A., Barroso C.,
RA   Diem A., Kratz C.P., Dvorsky R., Ahmadian M.R., Zenker M.;
RT   "Myopathy caused by HRAS germline mutations: implications for
RT   disturbed myogenic differentiation in the presence of constitutive
RT   HRas activation.";
RL   J. Med. Genet. 44:459-462(2007).
RN   [50]
RP   VARIANTS CSTLO ILE-58 AND VAL-146.
RX   PubMed=18247425; DOI=10.1002/ajmg.a.32227;
RA   Gripp K.W., Innes A.M., Axelrad M.E., Gillan T.L., Parboosingh J.S.,
RA   Davies C., Leonard N.J., Lapointe M., Doyle D., Catalano S.,
RA   Nicholson L., Stabley D.L., Sol-Church K.;
RT   "Costello syndrome associated with novel germline HRAS mutations: an
RT   attenuated phenotype?";
RL   Am. J. Med. Genet. A 146:683-690(2008).
RN   [51]
RP   VARIANTS CSTLO ASP-12 AND CYS-12.
RX   PubMed=18039947; DOI=10.1136/jmg.2007.054411;
RA   Lo I.F., Brewer C., Shannon N., Shorto J., Tang B., Black G.,
RA   Soo M.T., Ng D.K., Lam S.T., Kerr B.;
RT   "Severe neonatal manifestations of Costello syndrome.";
RL   J. Med. Genet. 45:167-171(2008).
RN   [52]
RP   VARIANT CSTLO GLU-37 INS.
RX   PubMed=19995790; DOI=10.1093/hmg/ddp548;
RA   Gremer L., De Luca A., Merbitz-Zahradnik T., Dallapiccola B.,
RA   Morlot S., Tartaglia M., Kutsche K., Ahmadian M.R., Rosenberger G.;
RT   "Duplication of Glu37 in the switch I region of HRAS impairs
RT   effector/GAP binding and underlies Costello syndrome by promoting
RT   enhanced growth factor-dependent MAPK and AKT activation.";
RL   Hum. Mol. Genet. 19:790-802(2010).
RN   [53]
RP   VARIANT SFM ARG-13, AND CHARACTERIZATION OF VARIANT SFM ARG-13.
RX   PubMed=22683711; DOI=10.1038/ng.2316;
RA   Groesser L., Herschberger E., Ruetten A., Ruivenkamp C., Lopriore E.,
RA   Zutt M., Langmann T., Singer S., Klingseisen L.,
RA   Schneider-Brachert W., Toll A., Real F.X., Landthaler M., Hafner C.;
RT   "Postzygotic HRAS and KRAS mutations cause nevus sebaceous and
RT   Schimmelpenning syndrome.";
RL   Nat. Genet. 44:783-787(2012).
CC   -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase
CC       activity. {ECO:0000269|PubMed:12740440,
CC       ECO:0000269|PubMed:14500341, ECO:0000269|PubMed:9020151}.
CC   -!- ENZYME REGULATION: Alternates between an inactive form bound to
CC       GDP and an active form bound to GTP. Activated by a guanine
CC       nucleotide-exchange factor (GEF) and inactivated by a GTPase-
CC       activating protein (GAP).
CC   -!- SUBUNIT: In its GTP-bound form interacts with PLCE1. Interacts
CC       with TBC1D10C. Interacts with RGL3. Interacts with HSPD1. Found in
CC       a complex with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14.
CC       Interacts (active GTP-bound form) with RGS14 (via RBD 1 domain)
CC       (By similarity). Forms a signaling complex with RASGRP1 and DGKZ.
CC       Interacts with RASSF5. Interacts with PDE6D. Interacts with IKZF3.
CC       Interacts with GNB2L1. Interacts with PIK3CG; the interaction is
CC       required for membrane recruitment and beta-gamma G protein dimer-
CC       dependent activation of the PI3K gamma complex PIK3CG:PIK3R6 (By
CC       similarity). Interacts with RAPGEF2. {ECO:0000250,
CC       ECO:0000269|PubMed:10369681, ECO:0000269|PubMed:10608844,
CC       ECO:0000269|PubMed:11022048, ECO:0000269|PubMed:11257115,
CC       ECO:0000269|PubMed:11598133, ECO:0000269|PubMed:11980706,
CC       ECO:0000269|PubMed:14500341, ECO:0000269|PubMed:17230191,
CC       ECO:0000269|PubMed:18596699, ECO:0000269|PubMed:9219684}.
CC   -!- INTERACTION:
CC       Q7Z569:BRAP; NbExp=3; IntAct=EBI-350145, EBI-349900;
CC       P42337:Pik3ca (xeno); NbExp=2; IntAct=EBI-350145, EBI-641748;
CC       O00329:PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-718309;
CC       O00329-2:PIK3CD; NbExp=2; IntAct=EBI-350145, EBI-6470902;
CC       Q9Z0S9:Rabac1 (xeno); NbExp=4; IntAct=EBI-350145, EBI-476965;
CC       P04049:RAF1; NbExp=14; IntAct=EBI-350145, EBI-365996;
CC       Q12967:RALGDS; NbExp=2; IntAct=EBI-350145, EBI-365861;
CC       Q9EQZ6:Rapgef4 (xeno); NbExp=3; IntAct=EBI-350145, EBI-772212;
CC       Q9NS23-2:RASSF1; NbExp=2; IntAct=EBI-350145, EBI-438698;
CC       Q8WWW0:RASSF5; NbExp=2; IntAct=EBI-350145, EBI-367390;
CC       Q5EBH1:Rassf5 (xeno); NbExp=11; IntAct=EBI-350145, EBI-960530;
CC       Q5EBH1-2:Rassf5 (xeno); NbExp=3; IntAct=EBI-350145, EBI-960547;
CC       Q13671:RIN1; NbExp=5; IntAct=EBI-350145, EBI-366017;
CC       Q07889:SOS1; NbExp=8; IntAct=EBI-350145, EBI-297487;
CC   -!- SUBCELLULAR LOCATION: Cell membrane. Cell membrane; Lipid-anchor;
CC       Cytoplasmic side. Golgi apparatus. Golgi apparatus membrane;
CC       Lipid-anchor. Note=The active GTP-bound form is localized most
CC       strongly to membranes than the inactive GDP-bound form (By
CC       similarity). Shuttles between the plasma membrane and the Golgi
CC       apparatus. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm. Cytoplasm,
CC       perinuclear region. Note=Colocalizes with GNB2L1 to the
CC       perinuclear region.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=H-Ras4A, p21;
CC         IsoId=P01112-1; Sequence=Displayed;
CC       Name=2; Synonyms=H-RasIDX, p19;
CC         IsoId=P01112-2; Sequence=VSP_041597;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:14500341}.
CC   -!- PTM: Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous
CC       cycle of de- and re-palmitoylation regulates rapid exchange
CC       between plasma membrane and Golgi.
CC   -!- PTM: S-nitrosylated; critical for redox regulation. Important for
CC       stimulating guanine nucleotide exchange. No structural
CC       perturbation on nitrosylation.
CC   -!- PTM: The covalent modification of cysteine by 15-deoxy-Delta12,14-
CC       prostaglandin-J2 is autocatalytic and reversible. It may occur as
CC       an alternative to other cysteine modifications, such as S-
CC       nitrosylation and S-palmitoylation.
CC   -!- PTM: Acetylation at Lys-104 prevents interaction with guanine
CC       nucleotide exchange factors (GEFs). {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=6223; Mass_error=2; Method=Electrospray;
CC       Range=112-166; Evidence={ECO:0000269|PubMed:9020151};
CC   -!- MASS SPECTROMETRY: Mass=6253; Mass_error=2; Method=Electrospray;
CC       Range=112-166; Note=Includes one nitric oxide molecule.;
CC       Evidence={ECO:0000269|PubMed:9020151};
CC   -!- DISEASE: Costello syndrome (CSTLO) [MIM:218040]: A rare condition
CC       characterized by prenatally increased growth, postnatal growth
CC       deficiency, mental retardation, distinctive facial appearance,
CC       cardiovascular abnormalities (typically pulmonic stenosis,
CC       hypertrophic cardiomyopathy and/or atrial tachycardia), tumor
CC       predisposition, skin and musculoskeletal abnormalities.
CC       {ECO:0000269|PubMed:16170316, ECO:0000269|PubMed:16329078,
CC       ECO:0000269|PubMed:16443854, ECO:0000269|PubMed:17054105,
CC       ECO:0000269|PubMed:18039947, ECO:0000269|PubMed:18247425,
CC       ECO:0000269|PubMed:19995790}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Congenital myopathy with excess of muscle spindles
CC       (CMEMS) [MIM:218040]: Variant of Costello syndrome.
CC       {ECO:0000269|PubMed:17412879}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]: A
CC       rare type of thyroid cancer accounting for only about 3-10% of all
CC       differentiated thyroid cancers. These neoplasms are considered a
CC       variant of follicular carcinoma of the thyroid and are referred to
CC       as follicular carcinoma, oxyphilic type.
CC       {ECO:0000269|PubMed:12727991}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Mutations which change positions 12, 13 or 61
CC       activate the potential of HRAS to transform cultured cells and are
CC       implicated in a variety of human tumors.
CC   -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy
CC       originating in tissues of the urinary bladder. It often presents
CC       with multiple tumors appearing at different times and at different
CC       sites in the bladder. Most bladder cancers are transitional cell
CC       carcinomas that begin in cells that normally make up the inner
CC       lining of the bladder. Other types of bladder cancer include
CC       squamous cell carcinoma (cancer that begins in thin, flat cells)
CC       and adenocarcinoma (cancer that begins in cells that make and
CC       release mucus and other fluids). Bladder cancer is a complex
CC       disorder with both genetic and environmental influences.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Schimmelpenning-Feuerstein-Mims syndrome (SFM)
CC       [MIM:163200]: A disease characterized by sebaceous nevi, often on
CC       the face, associated with variable ipsilateral abnormalities of
CC       the central nervous system, ocular anomalies, and skeletal
CC       defects. Many oral manifestations have been reported, not only
CC       including hypoplastic and malformed teeth, and mucosal
CC       papillomatosis, but also ankyloglossia, hemihyperplastic tongue,
CC       intraoral nevus, giant cell granuloma, ameloblastoma, bone cysts,
CC       follicular cysts, oligodontia, and odontodysplasia. Sebaceous nevi
CC       follow the lines of Blaschko and these can continue as linear
CC       intraoral lesions, as in mucosal papillomatosis.
CC       {ECO:0000269|PubMed:22683711}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HRASID108.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J00277; AAB02605.1; -; Genomic_DNA.
DR   EMBL; AJ437024; CAD24594.1; -; mRNA.
DR   EMBL; AF493916; AAM12630.1; -; mRNA.
DR   EMBL; CR536579; CAG38816.1; -; mRNA.
DR   EMBL; CR542271; CAG47067.1; -; mRNA.
DR   EMBL; BT019421; AAV38228.1; -; mRNA.
DR   EMBL; EF015887; ABI97389.1; -; Genomic_DNA.
DR   EMBL; AB451336; BAG70150.1; -; mRNA.
DR   EMBL; AB451485; BAG70299.1; -; mRNA.
DR   EMBL; CH471158; EAX02337.1; -; Genomic_DNA.
DR   EMBL; CH471158; EAX02338.1; -; Genomic_DNA.
DR   EMBL; BC006499; AAH06499.1; -; mRNA.
DR   EMBL; BC095471; AAH95471.1; -; mRNA.
DR   EMBL; M17232; AAA35685.1; -; Genomic_DNA.
DR   CCDS; CCDS7698.1; -. [P01112-1]
DR   CCDS; CCDS7699.1; -. [P01112-2]
DR   PIR; A93299; TVHUH.
DR   RefSeq; NP_001123914.1; NM_001130442.1. [P01112-1]
DR   RefSeq; NP_005334.1; NM_005343.2. [P01112-1]
DR   RefSeq; NP_789765.1; NM_176795.3. [P01112-2]
DR   UniGene; Hs.37003; -.
DR   PDB; 121P; X-ray; 1.54 A; A=1-166.
DR   PDB; 1AA9; NMR; -; A=1-171.
DR   PDB; 1AGP; X-ray; 2.30 A; A=1-166.
DR   PDB; 1BKD; X-ray; 2.80 A; R=1-166.
DR   PDB; 1CLU; X-ray; 1.70 A; A=1-166.
DR   PDB; 1CRP; NMR; -; A=1-166.
DR   PDB; 1CRQ; NMR; -; A=1-166.
DR   PDB; 1CRR; NMR; -; A=1-166.
DR   PDB; 1CTQ; X-ray; 1.26 A; A=1-166.
DR   PDB; 1GNP; X-ray; 2.70 A; A=1-166.
DR   PDB; 1GNQ; X-ray; 2.50 A; A=1-166.
DR   PDB; 1GNR; X-ray; 1.85 A; A=1-166.
DR   PDB; 1HE8; X-ray; 3.00 A; B=1-166.
DR   PDB; 1IAQ; X-ray; 2.90 A; A/B/C=1-166.
DR   PDB; 1IOZ; X-ray; 2.00 A; A=1-171.
DR   PDB; 1JAH; X-ray; 1.80 A; A=1-166.
DR   PDB; 1JAI; X-ray; 1.80 A; A=1-166.
DR   PDB; 1K8R; X-ray; 3.00 A; A=1-166.
DR   PDB; 1LF0; X-ray; 1.70 A; A=1-166.
DR   PDB; 1LF5; X-ray; 1.70 A; A=1-166.
DR   PDB; 1LFD; X-ray; 2.10 A; B/D=1-167.
DR   PDB; 1NVU; X-ray; 2.20 A; Q/R=1-166.
DR   PDB; 1NVV; X-ray; 2.18 A; Q/R=1-166.
DR   PDB; 1NVW; X-ray; 2.70 A; Q/R=1-166.
DR   PDB; 1NVX; X-ray; 3.20 A; Q/R=1-166.
DR   PDB; 1P2S; X-ray; 2.45 A; A=1-166.
DR   PDB; 1P2T; X-ray; 2.00 A; A=1-166.
DR   PDB; 1P2U; X-ray; 2.00 A; A=1-166.
DR   PDB; 1P2V; X-ray; 2.30 A; A=1-166.
DR   PDB; 1PLJ; X-ray; 2.80 A; A=1-166.
DR   PDB; 1PLK; X-ray; 2.80 A; A=1-166.
DR   PDB; 1PLL; X-ray; 2.80 A; A=1-166.
DR   PDB; 1Q21; X-ray; 2.20 A; A=1-171.
DR   PDB; 1QRA; X-ray; 1.60 A; A=1-166.
DR   PDB; 1RVD; X-ray; 1.90 A; A=1-166.
DR   PDB; 1WQ1; X-ray; 2.50 A; R=1-166.
DR   PDB; 1XCM; X-ray; 1.84 A; A=1-167.
DR   PDB; 1XD2; X-ray; 2.70 A; A/B=1-166.
DR   PDB; 1XJ0; X-ray; 1.70 A; A=1-166.
DR   PDB; 1ZVQ; X-ray; 2.00 A; A=1-166.
DR   PDB; 1ZW6; X-ray; 1.50 A; A=1-166.
DR   PDB; 221P; X-ray; 2.30 A; A=1-166.
DR   PDB; 2C5L; X-ray; 1.90 A; A/B=1-166.
DR   PDB; 2CE2; X-ray; 1.00 A; X=1-166.
DR   PDB; 2CL0; X-ray; 1.80 A; X=1-166.
DR   PDB; 2CL6; X-ray; 1.24 A; X=1-166.
DR   PDB; 2CL7; X-ray; 1.25 A; X=1-166.
DR   PDB; 2CLC; X-ray; 1.30 A; X=1-166.
DR   PDB; 2CLD; X-ray; 1.22 A; X=1-166.
DR   PDB; 2EVW; X-ray; 1.05 A; X=1-166.
DR   PDB; 2GDP; Model; -; A=1-171.
DR   PDB; 2LCF; NMR; -; A=1-166.
DR   PDB; 2LWI; NMR; -; A=1-166.
DR   PDB; 2Q21; X-ray; 2.20 A; A=1-171.
DR   PDB; 2QUZ; X-ray; 1.49 A; A=1-166.
DR   PDB; 2RGA; X-ray; 1.90 A; A=1-166.
DR   PDB; 2RGB; X-ray; 1.35 A; A=1-166.
DR   PDB; 2RGC; X-ray; 1.60 A; A=1-166.
DR   PDB; 2RGD; X-ray; 2.00 A; A=1-166.
DR   PDB; 2RGE; X-ray; 1.40 A; A=1-166.
DR   PDB; 2RGG; X-ray; 1.45 A; A=1-166.
DR   PDB; 2UZI; X-ray; 2.00 A; R=1-166.
DR   PDB; 2VH5; X-ray; 2.70 A; R=1-166.
DR   PDB; 2X1V; X-ray; 1.70 A; A=1-166.
DR   PDB; 3DDC; X-ray; 1.80 A; A=1-166.
DR   PDB; 3I3S; X-ray; 1.36 A; R=1-166.
DR   PDB; 3K8Y; X-ray; 1.30 A; A=1-166.
DR   PDB; 3K9L; X-ray; 1.80 A; A/B/C=1-166.
DR   PDB; 3K9N; X-ray; 2.00 A; A=1-166.
DR   PDB; 3KKM; X-ray; 1.70 A; A=1-166.
DR   PDB; 3KKN; X-ray; 2.09 A; A=1-166.
DR   PDB; 3KUD; X-ray; 2.15 A; A=1-166.
DR   PDB; 3L8Y; X-ray; 2.02 A; A=1-166.
DR   PDB; 3L8Z; X-ray; 1.44 A; A=1-166.
DR   PDB; 3LBH; X-ray; 1.85 A; A=1-166.
DR   PDB; 3LBI; X-ray; 2.09 A; A=1-166.
DR   PDB; 3LBN; X-ray; 1.86 A; A=1-166.
DR   PDB; 3LO5; X-ray; 2.57 A; A/C/E=1-166.
DR   PDB; 3OIU; X-ray; 1.32 A; A=1-166.
DR   PDB; 3OIV; X-ray; 1.84 A; A=1-166.
DR   PDB; 3OIW; X-ray; 1.30 A; A=1-166.
DR   PDB; 3RRY; X-ray; 1.60 A; A=1-166.
DR   PDB; 3RRZ; X-ray; 1.60 A; A=1-166.
DR   PDB; 3RS0; X-ray; 1.40 A; A=1-166.
DR   PDB; 3RS2; X-ray; 1.84 A; A=1-166.
DR   PDB; 3RS3; X-ray; 1.52 A; A=1-166.
DR   PDB; 3RS4; X-ray; 1.70 A; A=1-166.
DR   PDB; 3RS5; X-ray; 1.68 A; A=1-166.
DR   PDB; 3RS7; X-ray; 1.70 A; A=1-166.
DR   PDB; 3RSL; X-ray; 1.70 A; A=1-166.
DR   PDB; 3RSO; X-ray; 1.60 A; A=1-166.
DR   PDB; 3TGP; X-ray; 1.31 A; A=1-166.
DR   PDB; 421P; X-ray; 2.20 A; A=1-166.
DR   PDB; 4DLR; X-ray; 1.32 A; A=1-166.
DR   PDB; 4DLS; X-ray; 1.82 A; A=1-166.
DR   PDB; 4DLT; X-ray; 1.70 A; A=1-166.
DR   PDB; 4DLU; X-ray; 1.60 A; A=1-166.
DR   PDB; 4DLV; X-ray; 1.57 A; A=1-166.
DR   PDB; 4DLW; X-ray; 1.72 A; A=1-166.
DR   PDB; 4DLX; X-ray; 1.73 A; A=1-166.
DR   PDB; 4DLY; X-ray; 1.57 A; A=1-166.
DR   PDB; 4DLZ; X-ray; 1.66 A; A=1-166.
DR   PDB; 4DST; X-ray; 2.30 A; A=2-167.
DR   PDB; 4DSU; X-ray; 1.70 A; A=2-167.
DR   PDB; 4EFL; X-ray; 1.90 A; A=1-166.
DR   PDB; 4EFM; X-ray; 1.90 A; A=1-166.
DR   PDB; 4EFN; X-ray; 2.30 A; A=1-166.
DR   PDB; 4G0N; X-ray; 2.45 A; A=1-166.
DR   PDB; 4G3X; X-ray; 3.25 A; A=1-166.
DR   PDB; 4K81; X-ray; 2.40 A; B/D/F/H=1-166.
DR   PDB; 4L9S; X-ray; 1.61 A; A=1-166.
DR   PDB; 4L9W; X-ray; 1.95 A; A=1-166.
DR   PDB; 4NYI; X-ray; 2.96 A; Q/R=1-166.
DR   PDB; 4NYJ; X-ray; 2.85 A; Q/R=1-166.
DR   PDB; 4NYM; X-ray; 3.55 A; Q/R=1-166.
DR   PDB; 4Q21; X-ray; 2.00 A; A=1-189.
DR   PDB; 4URU; X-ray; 2.83 A; R=1-166.
DR   PDB; 4URV; X-ray; 2.58 A; R=1-166.
DR   PDB; 4URW; X-ray; 2.76 A; R=1-166.
DR   PDB; 4URX; X-ray; 2.49 A; R=1-166.
DR   PDB; 4URY; X-ray; 2.47 A; R=1-166.
DR   PDB; 4URZ; X-ray; 2.24 A; R=1-166.
DR   PDB; 4US0; X-ray; 2.17 A; R=1-166.
DR   PDB; 4US1; X-ray; 2.65 A; R=1-166.
DR   PDB; 4US2; X-ray; 2.48 A; R=1-166.
DR   PDB; 521P; X-ray; 2.60 A; A=1-166.
DR   PDB; 5P21; X-ray; 1.35 A; A=1-166.
DR   PDB; 621P; X-ray; 2.40 A; A=1-166.
DR   PDB; 6Q21; X-ray; 1.95 A; A/B/C/D=1-171.
DR   PDB; 721P; X-ray; 2.00 A; A=1-166.
DR   PDB; 821P; X-ray; 1.50 A; A=1-166.
DR   PDBsum; 121P; -.
DR   PDBsum; 1AA9; -.
DR   PDBsum; 1AGP; -.
DR   PDBsum; 1BKD; -.
DR   PDBsum; 1CLU; -.
DR   PDBsum; 1CRP; -.
DR   PDBsum; 1CRQ; -.
DR   PDBsum; 1CRR; -.
DR   PDBsum; 1CTQ; -.
DR   PDBsum; 1GNP; -.
DR   PDBsum; 1GNQ; -.
DR   PDBsum; 1GNR; -.
DR   PDBsum; 1HE8; -.
DR   PDBsum; 1IAQ; -.
DR   PDBsum; 1IOZ; -.
DR   PDBsum; 1JAH; -.
DR   PDBsum; 1JAI; -.
DR   PDBsum; 1K8R; -.
DR   PDBsum; 1LF0; -.
DR   PDBsum; 1LF5; -.
DR   PDBsum; 1LFD; -.
DR   PDBsum; 1NVU; -.
DR   PDBsum; 1NVV; -.
DR   PDBsum; 1NVW; -.
DR   PDBsum; 1NVX; -.
DR   PDBsum; 1P2S; -.
DR   PDBsum; 1P2T; -.
DR   PDBsum; 1P2U; -.
DR   PDBsum; 1P2V; -.
DR   PDBsum; 1PLJ; -.
DR   PDBsum; 1PLK; -.
DR   PDBsum; 1PLL; -.
DR   PDBsum; 1Q21; -.
DR   PDBsum; 1QRA; -.
DR   PDBsum; 1RVD; -.
DR   PDBsum; 1WQ1; -.
DR   PDBsum; 1XCM; -.
DR   PDBsum; 1XD2; -.
DR   PDBsum; 1XJ0; -.
DR   PDBsum; 1ZVQ; -.
DR   PDBsum; 1ZW6; -.
DR   PDBsum; 221P; -.
DR   PDBsum; 2C5L; -.
DR   PDBsum; 2CE2; -.
DR   PDBsum; 2CL0; -.
DR   PDBsum; 2CL6; -.
DR   PDBsum; 2CL7; -.
DR   PDBsum; 2CLC; -.
DR   PDBsum; 2CLD; -.
DR   PDBsum; 2EVW; -.
DR   PDBsum; 2GDP; -.
DR   PDBsum; 2LCF; -.
DR   PDBsum; 2LWI; -.
DR   PDBsum; 2Q21; -.
DR   PDBsum; 2QUZ; -.
DR   PDBsum; 2RGA; -.
DR   PDBsum; 2RGB; -.
DR   PDBsum; 2RGC; -.
DR   PDBsum; 2RGD; -.
DR   PDBsum; 2RGE; -.
DR   PDBsum; 2RGG; -.
DR   PDBsum; 2UZI; -.
DR   PDBsum; 2VH5; -.
DR   PDBsum; 2X1V; -.
DR   PDBsum; 3DDC; -.
DR   PDBsum; 3I3S; -.
DR   PDBsum; 3K8Y; -.
DR   PDBsum; 3K9L; -.
DR   PDBsum; 3K9N; -.
DR   PDBsum; 3KKM; -.
DR   PDBsum; 3KKN; -.
DR   PDBsum; 3KUD; -.
DR   PDBsum; 3L8Y; -.
DR   PDBsum; 3L8Z; -.
DR   PDBsum; 3LBH; -.
DR   PDBsum; 3LBI; -.
DR   PDBsum; 3LBN; -.
DR   PDBsum; 3LO5; -.
DR   PDBsum; 3OIU; -.
DR   PDBsum; 3OIV; -.
DR   PDBsum; 3OIW; -.
DR   PDBsum; 3RRY; -.
DR   PDBsum; 3RRZ; -.
DR   PDBsum; 3RS0; -.
DR   PDBsum; 3RS2; -.
DR   PDBsum; 3RS3; -.
DR   PDBsum; 3RS4; -.
DR   PDBsum; 3RS5; -.
DR   PDBsum; 3RS7; -.
DR   PDBsum; 3RSL; -.
DR   PDBsum; 3RSO; -.
DR   PDBsum; 3TGP; -.
DR   PDBsum; 421P; -.
DR   PDBsum; 4DLR; -.
DR   PDBsum; 4DLS; -.
DR   PDBsum; 4DLT; -.
DR   PDBsum; 4DLU; -.
DR   PDBsum; 4DLV; -.
DR   PDBsum; 4DLW; -.
DR   PDBsum; 4DLX; -.
DR   PDBsum; 4DLY; -.
DR   PDBsum; 4DLZ; -.
DR   PDBsum; 4DST; -.
DR   PDBsum; 4DSU; -.
DR   PDBsum; 4EFL; -.
DR   PDBsum; 4EFM; -.
DR   PDBsum; 4EFN; -.
DR   PDBsum; 4G0N; -.
DR   PDBsum; 4G3X; -.
DR   PDBsum; 4K81; -.
DR   PDBsum; 4L9S; -.
DR   PDBsum; 4L9W; -.
DR   PDBsum; 4NYI; -.
DR   PDBsum; 4NYJ; -.
DR   PDBsum; 4NYM; -.
DR   PDBsum; 4Q21; -.
DR   PDBsum; 4URU; -.
DR   PDBsum; 4URV; -.
DR   PDBsum; 4URW; -.
DR   PDBsum; 4URX; -.
DR   PDBsum; 4URY; -.
DR   PDBsum; 4URZ; -.
DR   PDBsum; 4US0; -.
DR   PDBsum; 4US1; -.
DR   PDBsum; 4US2; -.
DR   PDBsum; 521P; -.
DR   PDBsum; 5P21; -.
DR   PDBsum; 621P; -.
DR   PDBsum; 6Q21; -.
DR   PDBsum; 721P; -.
DR   PDBsum; 821P; -.
DR   DisProt; DP00153; -.
DR   ProteinModelPortal; P01112; -.
DR   SMR; P01112; 1-166.
DR   BioGrid; 109501; 76.
DR   DIP; DIP-1050N; -.
DR   IntAct; P01112; 48.
DR   MINT; MINT-5002362; -.
DR   STRING; 9606.ENSP00000309845; -.
DR   BindingDB; P01112; -.
DR   ChEMBL; CHEMBL2167; -.
DR   GuidetoPHARMACOLOGY; 2822; -.
DR   PhosphoSite; P01112; -.
DR   BioMuta; HRAS; -.
DR   DMDM; 131869; -.
DR   PaxDb; P01112; -.
DR   PRIDE; P01112; -.
DR   DNASU; 3265; -.
DR   Ensembl; ENST00000311189; ENSP00000309845; ENSG00000174775.
DR   Ensembl; ENST00000397594; ENSP00000380722; ENSG00000174775. [P01112-2]
DR   Ensembl; ENST00000397596; ENSP00000380723; ENSG00000174775.
DR   Ensembl; ENST00000417302; ENSP00000388246; ENSG00000174775. [P01112-2]
DR   Ensembl; ENST00000451590; ENSP00000407586; ENSG00000174775.
DR   Ensembl; ENST00000493230; ENSP00000434023; ENSG00000174775. [P01112-2]
DR   Ensembl; ENST00000610977; ENSP00000480686; ENSG00000276536.
DR   Ensembl; ENST00000615062; ENSP00000482366; ENSG00000276536.
DR   Ensembl; ENST00000616241; ENSP00000480317; ENSG00000276536. [P01112-2]
DR   GeneID; 3265; -.
DR   KEGG; hsa:3265; -.
DR   UCSC; uc001lpv.3; human. [P01112-1]
DR   UCSC; uc010qvw.2; human. [P01112-2]
DR   CTD; 3265; -.
DR   GeneCards; GC11M000522; -.
DR   GeneReviews; HRAS; -.
DR   HGNC; HGNC:5173; HRAS.
DR   HPA; CAB002015; -.
DR   HPA; HPA049830; -.
DR   MIM; 109800; phenotype.
DR   MIM; 163200; phenotype.
DR   MIM; 190020; gene.
DR   MIM; 218040; phenotype.
DR   MIM; 607464; phenotype.
DR   neXtProt; NX_P01112; -.
DR   Orphanet; 3071; Costello syndrome.
DR   Orphanet; 2612; Linear nevus sebaceus syndrome.
DR   Orphanet; 2874; Phakomatosis pigmentokeratotica.
DR   PharmGKB; PA29444; -.
DR   eggNOG; COG1100; -.
DR   GeneTree; ENSGT00780000121849; -.
DR   HOGENOM; HOG000233973; -.
DR   HOVERGEN; HBG009351; -.
DR   InParanoid; P01112; -.
DR   KO; K02833; -.
DR   OMA; DCMNCKC; -.
DR   OrthoDB; EOG7QVM41; -.
DR   PhylomeDB; P01112; -.
DR   TreeFam; TF312796; -.
DR   Reactome; REACT_111040; Signaling by SCF-KIT.
DR   Reactome; REACT_115852; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; REACT_115854; GRB2 events in ERBB2 signaling.
DR   Reactome; REACT_115993; SHC1 events in ERBB2 signaling.
DR   Reactome; REACT_116005; SHC1 events in ERBB4 signaling.
DR   Reactome; REACT_118778; Activation of RAS in B cells.
DR   Reactome; REACT_12033; Signalling to RAS.
DR   Reactome; REACT_12065; p38MAPK events.
DR   Reactome; REACT_121096; EGFR Transactivation by Gastrin.
DR   Reactome; REACT_12579; SHC1 events in EGFR signaling.
DR   Reactome; REACT_12606; GRB2 events in EGFR signaling.
DR   Reactome; REACT_12621; Tie2 Signaling.
DR   Reactome; REACT_147814; DAP12 signaling.
DR   Reactome; REACT_163701; FCERI mediated MAPK activation.
DR   Reactome; REACT_17025; Downstream signal transduction.
DR   Reactome; REACT_18334; NCAM signaling for neurite out-growth.
DR   Reactome; REACT_20546; Ras activation uopn Ca2+ infux through NMDA receptor.
DR   Reactome; REACT_2077; RAF activation.
DR   Reactome; REACT_23891; Interleukin receptor SHC signaling.
DR   Reactome; REACT_263952; EPHB-mediated forward signaling.
DR   Reactome; REACT_264273; VEGFR2 mediated cell proliferation.
DR   Reactome; REACT_267817; Constitutive Signaling by EGFRvIII.
DR   Reactome; REACT_355069; FRS-mediated FGFR2 signaling.
DR   Reactome; REACT_355159; SHC-mediated cascade:FGFR4.
DR   Reactome; REACT_355194; SHC-mediated cascade:FGFR1.
DR   Reactome; REACT_355197; SHC-mediated cascade:FGFR3.
DR   Reactome; REACT_355202; Signaling by FGFR4 mutants.
DR   Reactome; REACT_355212; FRS-mediated FGFR3 signaling.
DR   Reactome; REACT_355221; Signaling by FGFR1 mutants.
DR   Reactome; REACT_355225; SHC-mediated cascade:FGFR2.
DR   Reactome; REACT_355313; Signaling by FGFR3 mutants.
DR   Reactome; REACT_355503; CD209 (DC-SIGN) signaling.
DR   Reactome; REACT_355511; Signaling by FGFR2 mutants.
DR   Reactome; REACT_355580; FRS2-mediated FGFR4 signaling.
DR   Reactome; REACT_355584; FRS-mediated FGFR1 signaling.
DR   Reactome; REACT_524; SOS-mediated signalling.
DR   Reactome; REACT_614; RAF phosphorylates MEK.
DR   Reactome; REACT_661; SHC-mediated signalling.
DR   Reactome; REACT_962; MEK activation.
DR   SignaLink; P01112; -.
DR   EvolutionaryTrace; P01112; -.
DR   GeneWiki; HRAS; -.
DR   GenomeRNAi; 3265; -.
DR   NextBio; 12961; -.
DR   PRO; PR:P01112; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; P01112; -.
DR   CleanEx; HS_HRAS; -.
DR   ExpressionAtlas; P01112; baseline and differential.
DR   Genevisible; P01112; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003924; F:GTPase activity; IDA:WormBase.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0090398; P:cellular senescence; IDA:BHF-UCL.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0006897; P:endocytosis; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; IDA:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; IDA:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IDA:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:2000630; P:positive regulation of miRNA metabolic process; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:1900029; P:positive regulation of ruffle assembly; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0090303; P:positive regulation of wound healing; IDA:BHF-UCL.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0007265; P:Ras protein signal transduction; IDA:BHF-UCL.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0035176; P:social behavior; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007268; P:synaptic transmission; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 3.40.50.300; -; 1.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd_dom.
DR   InterPro; IPR001806; Small_GTPase.
DR   InterPro; IPR020849; Small_GTPase_Ras.
DR   PANTHER; PTHR24070; PTHR24070; 1.
DR   Pfam; PF00071; Ras; 1.
DR   PRINTS; PR00449; RASTRNSFRMNG.
DR   SMART; SM00173; RAS; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   TIGRFAMs; TIGR00231; small_GTP; 1.
DR   PROSITE; PS51421; RAS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Golgi apparatus; GTP-binding; Lipoprotein; Membrane;
KW   Methylation; Nucleotide-binding; Nucleus; Palmitate; Prenylation;
KW   Proto-oncogene; Reference proteome; S-nitrosylation.
FT   CHAIN         1    186       GTPase HRas.
FT                                /FTId=PRO_0000042996.
FT   INIT_MET      1      1       Removed; alternate. {ECO:0000269|Ref.12}.
FT   CHAIN         2    186       GTPase HRas, N-terminally processed.
FT                                /FTId=PRO_0000326476.
FT   PROPEP      187    189       Removed in mature form.
FT                                /FTId=PRO_0000042997.
FT   NP_BIND      10     17       GTP.
FT   NP_BIND      57     61       GTP.
FT   NP_BIND     116    119       GTP.
FT   REGION      166    185       Hypervariable region.
FT   MOTIF        32     40       Effector region.
FT   MOD_RES       1      1       N-acetylmethionine; in GTPase HRas;
FT                                alternate. {ECO:0000269|Ref.12}.
FT   MOD_RES       2      2       N-acetylthreonine; in GTPase HRas, N-
FT                                terminally processed.
FT                                {ECO:0000269|Ref.12}.
FT   MOD_RES     104    104       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P01116}.
FT   MOD_RES     118    118       S-nitrosocysteine.
FT                                {ECO:0000269|PubMed:9020151}.
FT   MOD_RES     186    186       Cysteine methyl ester.
FT                                {ECO:0000269|PubMed:8626715}.
FT   LIPID       181    181       S-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:15705808,
FT                                ECO:0000269|PubMed:16000296,
FT                                ECO:0000269|PubMed:2661017,
FT                                ECO:0000269|PubMed:8626715}.
FT   LIPID       184    184       S-(15-deoxy-Delta12,14-prostaglandin J2-
FT                                9-yl)cysteine; alternate.
FT                                {ECO:0000269|PubMed:12684535}.
FT   LIPID       184    184       S-palmitoyl cysteine; alternate.
FT                                {ECO:0000269|PubMed:15705808,
FT                                ECO:0000269|PubMed:16000296,
FT                                ECO:0000269|PubMed:2661017,
FT                                ECO:0000269|PubMed:8626715}.
FT   LIPID       186    186       S-farnesyl cysteine.
FT                                {ECO:0000269|PubMed:8626715}.
FT   VAR_SEQ     152    189       VEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKCVLS ->
FT                                SRSGSSSSSGTLWDPPGPM (in isoform 2).
FT                                {ECO:0000303|PubMed:14500341,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041597.
FT   VARIANT      12     12       G -> A (in CSTLO).
FT                                {ECO:0000269|PubMed:16170316,
FT                                ECO:0000269|PubMed:16329078,
FT                                ECO:0000269|PubMed:16443854}.
FT                                /FTId=VAR_026106.
FT   VARIANT      12     12       G -> C (in CSTLO).
FT                                {ECO:0000269|PubMed:16443854,
FT                                ECO:0000269|PubMed:18039947}.
FT                                /FTId=VAR_045975.
FT   VARIANT      12     12       G -> D (in CSTLO; severe mutation).
FT                                {ECO:0000269|PubMed:18039947}.
FT                                /FTId=VAR_068816.
FT   VARIANT      12     12       G -> E (in CSTLO).
FT                                {ECO:0000269|PubMed:16443854}.
FT                                /FTId=VAR_045976.
FT   VARIANT      12     12       G -> S (in CSTLO and CMEMS; also found in
FT                                patients with oral squamous cell
FT                                carcinoma). {ECO:0000269|PubMed:1459726,
FT                                ECO:0000269|PubMed:16170316,
FT                                ECO:0000269|PubMed:16329078,
FT                                ECO:0000269|PubMed:16443854,
FT                                ECO:0000269|PubMed:17054105,
FT                                ECO:0000269|PubMed:17412879}.
FT                                /FTId=VAR_006837.
FT   VARIANT      12     12       G -> V (in CSTLO, bladder carcinoma and
FT                                CMEMS; constitutively activated;
FT                                interacts and recruits PLCE1 to plasma
FT                                membrane; loss of interaction with and
FT                                recruitment to plasma membrane of PLCE1
FT                                when associated with F-32; loss of
FT                                interaction with PLCE1 when associated
FT                                with G-26, F-32 and S-35; no effect on
FT                                interaction with PLCE1 when associated
FT                                with A-29, G-34, G-37, N-38 and C-39; no
FT                                effect on subcellular location of isoform
FT                                2). {ECO:0000269|PubMed:11022048,
FT                                ECO:0000269|PubMed:15546861,
FT                                ECO:0000269|PubMed:16170316,
FT                                ECO:0000269|PubMed:17412879}.
FT                                /FTId=VAR_006836.
FT   VARIANT      13     13       G -> C (in CSTLO).
FT                                {ECO:0000269|PubMed:16329078}.
FT                                /FTId=VAR_026107.
FT   VARIANT      13     13       G -> D (in CSTLO).
FT                                {ECO:0000269|PubMed:16170316}.
FT                                /FTId=VAR_026108.
FT   VARIANT      13     13       G -> R (in SFM; somatic mutation; shows
FT                                constitutive activation of the MAPK and
FT                                PI3K-AKT signaling pathways).
FT                                {ECO:0000269|PubMed:22683711}.
FT                                /FTId=VAR_068817.
FT   VARIANT      22     22       Q -> K (in CMEMS).
FT                                {ECO:0000269|PubMed:17412879}.
FT                                /FTId=VAR_045977.
FT   VARIANT      37     37       E -> EE (in FCSS).
FT                                {ECO:0000269|PubMed:19995790}.
FT                                /FTId=VAR_068818.
FT   VARIANT      58     58       T -> I (in CSTLO).
FT                                {ECO:0000269|PubMed:18247425}.
FT                                /FTId=VAR_045978.
FT   VARIANT      61     61       Q -> K (in follicular thyroid carcinoma
FT                                samples; somatic mutation; increases
FT                                transformation of cultured cell lines;
FT                                dbSNP:rs28933406).
FT                                {ECO:0000269|PubMed:12727991,
FT                                ECO:0000269|PubMed:18073111}.
FT                                /FTId=VAR_045979.
FT   VARIANT      61     61       Q -> L (in melanoma; strongly reduced GTP
FT                                hydrolysis in the presence of RAF1;
FT                                increases transformation of cultured cell
FT                                lines). {ECO:0000269|PubMed:18073111}.
FT                                /FTId=VAR_006838.
FT   VARIANT      63     63       E -> K (in CMEMS).
FT                                {ECO:0000269|PubMed:17412879}.
FT                                /FTId=VAR_045980.
FT   VARIANT     117    117       K -> R (in CSTLO).
FT                                {ECO:0000269|PubMed:16443854}.
FT                                /FTId=VAR_045981.
FT   VARIANT     146    146       A -> T (in CSTLO).
FT                                {ECO:0000269|PubMed:17054105}.
FT                                /FTId=VAR_045982.
FT   VARIANT     146    146       A -> V (in CSTLO).
FT                                {ECO:0000269|PubMed:18247425}.
FT                                /FTId=VAR_045983.
FT   MUTAGEN      17     17       S->N: Dominant negative. Prevents PLCE1
FT                                EGF-induced recruitment to plasma
FT                                membrane. No effect on subcellular
FT                                location of isoform 2.
FT                                {ECO:0000269|PubMed:11022048,
FT                                ECO:0000269|PubMed:14500341}.
FT   MUTAGEN      26     26       N->G: Loss of interaction with PLCE1;
FT                                when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      29     29       V->A: No effect on interaction with
FT                                PLCE1; when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      32     32       Y->F: Loss of interaction and recruitment
FT                                to plasma membrane of PLCE1; when
FT                                associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      34     34       P->G: No effect on interaction with
FT                                PLCE1; when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      35     35       T->S: Loss of interaction with PLCE1;
FT                                when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      37     37       E->G: No effect on interaction with
FT                                PLCE1; when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      38     38       D->N: No effect on interaction with
FT                                PLCE1; when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      39     39       S->C: No effect on interaction with
FT                                PLCE1; when associated with V-12.
FT                                {ECO:0000269|PubMed:11022048}.
FT   MUTAGEN      59     59       A->T: Loss of GTPase activity and
FT                                creation of an autophosphorylation site.
FT   MUTAGEN      61     61       Q->I: Moderately increased transformation
FT                                of cultured cell lines.
FT                                {ECO:0000269|PubMed:18073111}.
FT   MUTAGEN      61     61       Q->V: Strongly increased transformation
FT                                of cultured cell lines.
FT                                {ECO:0000269|PubMed:18073111}.
FT   MUTAGEN      83     83       A->T: GTP-binding activity reduced by
FT                                factor of 30.
FT                                {ECO:0000269|PubMed:3088563}.
FT   MUTAGEN     118    118       C->S: Abolishes S-nitrosylation. No
FT                                stimulation of guanine nucleotide
FT                                exchange. {ECO:0000269|PubMed:12740440,
FT                                ECO:0000269|PubMed:9020151}.
FT   MUTAGEN     119    119       D->N: Loss of GTP-binding activity.
FT                                {ECO:0000269|PubMed:3088563}.
FT   MUTAGEN     144    144       T->I: GTP-binding activity reduced by
FT                                factor of 25.
FT                                {ECO:0000269|PubMed:3088563}.
FT   MUTAGEN     164    165       RQ->AV: Loss of GTP-binding activity.
FT                                {ECO:0000269|PubMed:3011420}.
FT   MUTAGEN     181    181       C->S: Exclusively localized in Golgi.
FT                                Non-specifically localized on all
FT                                endomembranes; when associated with S-
FT                                184. {ECO:0000269|PubMed:15705808,
FT                                ECO:0000269|PubMed:8626715}.
FT   MUTAGEN     184    184       C->S: Loss of S-(15-deoxy-Delta12,14-
FT                                prostaglandin J2-9-yl)cysteine
FT                                stimulation of Ras-GTPase activity.
FT                                Mainly localized in Golgi. Non-
FT                                specifically localized on all
FT                                endomembranes; when associated with S-
FT                                181. {ECO:0000269|PubMed:12684535,
FT                                ECO:0000269|PubMed:15705808,
FT                                ECO:0000269|PubMed:8626715}.
FT   STRAND        3     11       {ECO:0000244|PDB:2CE2}.
FT   STRAND       12     14       {ECO:0000244|PDB:4US0}.
FT   HELIX        16     25       {ECO:0000244|PDB:2CE2}.
FT   STRAND       27     31       {ECO:0000244|PDB:1XCM}.
FT   STRAND       34     37       {ECO:0000244|PDB:1XD2}.
FT   STRAND       38     46       {ECO:0000244|PDB:2CE2}.
FT   STRAND       49     57       {ECO:0000244|PDB:2CE2}.
FT   STRAND       60     63       {ECO:0000244|PDB:2CLD}.
FT   HELIX        66     74       {ECO:0000244|PDB:2CE2}.
FT   STRAND       76     83       {ECO:0000244|PDB:2CE2}.
FT   TURN         84     86       {ECO:0000244|PDB:1CRP}.
FT   HELIX        87    104       {ECO:0000244|PDB:2CE2}.
FT   STRAND      105    107       {ECO:0000244|PDB:6Q21}.
FT   STRAND      111    116       {ECO:0000244|PDB:2CE2}.
FT   STRAND      120    122       {ECO:0000244|PDB:2CLD}.
FT   HELIX       127    136       {ECO:0000244|PDB:2CE2}.
FT   STRAND      141    144       {ECO:0000244|PDB:2CE2}.
FT   TURN        146    148       {ECO:0000244|PDB:2CE2}.
FT   HELIX       152    164       {ECO:0000244|PDB:2CE2}.
SQ   SEQUENCE   189 AA;  21298 MW;  EE6DC2D933E2856A CRC64;
     MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG
     QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHQYREQI KRVKDSDDVP MVLVGNKCDL
     AARTVESRQA QDLARSYGIP YIETSAKTRQ GVEDAFYTLV REIRQHKLRK LNPPDESGPG
     CMSCKCVLS
//
